Hazneci E.Bayram N.Aki T.Do?an G.2024-08-042024-08-0420041019-214Xhttps://hdl.handle.net/11616/90924Bacground and Design: Our purpose was to determine the economic and medical aspects of superficial fungal infection treatments, that given in our clinic. Material and Method: A total of 112 patients with clinically proven and treated patients, suffered from superficial fungal infections were surveyed. Clinical types of the infection, microscopic examination results and the given treatments were analyzed. Evidence based updates were made and standard treatments determined for all clinical types of superficial fungal diseases. The treatments were compared with standard treatments. Results: Eighty-five of 112 patients (75.8%) who had been diagnosed as superficial fungal disease were microscopically positive. The chosen managements were two topical antimycotic (%26.2), one topical antimycotic only (%24.2), systemic itraconazole (%23.5) and systemic terbinafine (%21.5). Mostly T.pedis (%52.3), T.unguium (%20.8), T.versicolor (%10.7) and T.inguinalis (%8.7) were seen respectively. Conclusion: We need to ensure that we are treating our patients with the best available agent for their disease.trinfo:eu-repo/semantics/closedAccessSuperficial fungal infectionsTreatmentArticle38154602-s2.0-53549124172N/A